Ranking · Unmet Need
Trial Gap Index
Burden percentile minus active-trial percentile within the same scope. Positive values flag cancers with high mortality burden but comparatively few active trials. A quantitative signal, not an accusation (CLAUDE.md §324). Caveat (Phase 1): trial counts aggregate a cancer and its NCIt descendants only; registrations phrased at a broader level (e.g. "colorectal cancer" for colon and rectal cancer) are attributed to the broader entity, which can overstate the gap of narrower top-level sites.
Computedci-trial-gap-v1unit: percentile pointshigher = worseAll metrics
| Rank | Δ | Cancer | Trial Gap Index (percentile points) | Percentile | Confidence | Sources | Why #n? |
|---|---|---|---|---|---|---|---|
| 1 | = | Malignant Colon Neoplasm | +48 | 100 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606584 |
| 2 | ▲3 | Malignant Bladder Neoplasm | +24 | 96 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606586 |
| 2 | ▲2 | Malignant Laryngeal Neoplasm | +24 | 96 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606585 |
| 4 | ▼1 | Cutaneous Melanoma | +20 | 88 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606587 |
| 5 | ▲2 | Malignant Esophageal Neoplasm | +16 | 84 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606588 |
| 5 | ▲10 | Malignant Pancreatic Neoplasm | +16 | 84 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606589 |
| 7 | ▲11 | Malignant Prostate Neoplasm | +12 | 76 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606591 |
| 7 | ▲3 | Malignant Salivary Gland Neoplasm | +12 | 76 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606590 |
| 9 | ▲5 | Malignant Anal Neoplasm | +8 | 68 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606594 |
| 9 | ▲3 | Malignant Mesothelioma | +8 | 68 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606592 |
| 9 | = | Malignant Testicular Neoplasm | +8 | 68 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606593 |
| 12 | ▲5 | Malignant Kidney Neoplasm | +4 | 56 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606595 |
| 12 | ▲10 | Malignant Liver Neoplasm | +4 | 56 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606596 |
| 12 | ▲4 | Malignant Rectal Neoplasm | +4 | 56 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606597 |
| 15 | ▲8 | Malignant Lung Neoplasm | 0 | 44 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606598 |
| 15 | ▲9 | Malignant Thyroid Gland Neoplasm | 0 | 44 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606599 |
| 17 | ▲4 | Malignant Hypopharyngeal Neoplasm | -4 | 36 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606600 |
| 17 | ▲3 | Malignant Penile Neoplasm | -4 | 36 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606601 |
| 19 | ▲7 | Leukemia | -8 | 28 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606602 |
| 19 | ▲7 | Malignant Central Nervous System Neoplasm | -8 | 28 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606603 |
| 21 | ▲9 | Hodgkin Lymphoma | -16 | 20 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606604 |
| 21 | ▲8 | Malignant Gastric Neoplasm | -16 | 20 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606605 |
| 21 | ▲7 | Multiple Myeloma | -16 | 20 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606606 |
| 24 | ▲7 | Non-Hodgkin Lymphoma | -24 | 8 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606607 |
| 25 | ▲7 | Malignant Nasopharyngeal Neoplasm | -36 | 4 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606608 |
| 26 | ▲10 | Malignant Breast Neoplasm | -80 | 0 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2606609 |
Data updated 16 hours agoSource updated unknown26 eligible entities · inputs hash 6b318302c37a767f64a6c833